News

Fintel on MSN2d
JP Morgan Upgrades Sarepta Therapeutics (SRPT)
Fintel reports that on July 29, 2025, JP Morgan upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...
Why Sarepta's halted drug Elevidys is an issue for investors
Sarepta (SRPT) paused shipments of its top-selling gene therapy drug after the US Food and Drug Administration (FDA) raised ...